Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 2, 2000, Pages 605-612

  Marcic, Branislav M ^a   Erdös, Ervin G ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BRADYKININ; BRADYKININ RECEPTOR; CALPHOSTIN; CALYCULIN A; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; OKADAIC ACID; PHOSPHATASE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RAMIPRILAT; STAUROSPORINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARACHIDONIC ACID; BRADYKININ; CALCIUM; CELLS, CULTURED; CHO CELLS; CRICETINAE; DRUG INTERACTIONS; ENALAPRILAT; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; NAPHTHALENES; OKADAIC ACID; OXAZOLES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN KINASE C; PULMONARY ARTERY; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; TRANSFECTION;

EID: 0033913771     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ambrosioni E, Borghi C, Magnani B and the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators (1995) The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80-85.
2. Auch-Schwelk W, Bossaller C, Claus M, Walther B, Gräfe M and Fleck E (1993) ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 27:312-317.
3. Balsinde J and Dennis EA (1997) Function and inhibition of intracellular calcium-independent phospholipase A2. J Biol Chem 272:16069-16072.
4. Benzing T, Fleming I, Blaukat A, Müller-Esterl W and Busse R (1999) Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99:2034-2040.
5. Bhoola KD, Figueroa CD and Worthy K (1992) Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80.
6. Blaukat A, Abd Alia S, Lohse MJ and Müller-Esterl W (1996) Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts J Biol Chem 271:32366-32374.
7. 2. Proc Natl Acad Sci USA 84:6374-6378.
8. ω-nitro-L-arginine. Hypertension 18:683-688.
9. Campbell WB and Harder DR (1999) Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484-488.
10. Carretero OA and Scicli AG (1995) The kallikrein-kinin system as a regulator of cardiovascular and renal function, in Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. (Laragh JH and Brenner BM eds) pp 983-999, Raven Press Publishers, New York.
11. Dalemar LR, Jong Y-JI, Wilhelm B and Baenziger NL (1996) Protein kinases A and C rapidly modulate expression of human lung fibroblast B2 bradykinin receptor affinity forms. Eur J Cell Biol 69:236-244.
12. 1 MF-2 smooth muscle cells. J Biol Chem 272:17858-17866.
13. Deddish PA, Marcic B, Jackman HL, Wang H-Z, Skidgel RA and Erdös EG (1998) N-domain specific substrates and C-domain inhibitors of angiotensin converting enzyme: Angiotensin-(1-7) and keto-ACE. Hypertension 31:912-917.
14. 2 receptor selective agonist which is not broken down by either kininase I or kininase II. Eur J Pharmacol 155:193-195.
15. Erdös EG, Deddish PA and Marcic BM (1999) Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol Metab 10:223-229.
16. Gavras H (1994) Angiotensin converting enzyme inhibition and the heart. Hypertension 23:813-818.
17. Gjertsen BT, Cressey LI, Ruchaud S, Houge G, Lanotte M and Doskeland SO (1994) Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. J Cell Sci 107:3363-3377.
18. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153.
19. Hecker M, Pörsti K, Bara AT and Busse R (1994) Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: Interaction at the receptor level. Br J Pharmacol 111:238-244.
20. Hofmann J (1997) The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11:649-669.
21. Johnson AR (1980) Human pulmonary endothelial cells in culture. J Clin Invest 65:841-850.
22. 1, MF-2 smooth muscle cells. J Biol Chem 262:3098-3105.
23. Lewis EJ (1996) Angiotensin-converting enzyme inhibition in type I diabetic nephropathy, in Progression of Chronic Renal Diseases. Contributions in Nephrology (Koide H and Ichikawa I eds) vol 118, pp 206-213, Karger, Basel, Switzerland.
24. Linz W, Wiemer G, Gohlke P, Unger T and Schölkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49.
25. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ and Pitt B (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 94:258-265.
26. 2 receptor. Hypertension 33:835-843.
27. 2 bradykinin receptor by ACE inhibitors. J Biol Chem 275:16110-16118.
28. Margolius HS (1995) Kallikreins and kinins - Some unanswered questions about system characteristics and roles in human disease. Hypertension 26:221-229.
29. Minshall RD, Erdös EG and Vogel SM (1997a) Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol 80:A132-A136.
30. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B and Erdös EG (1997b) Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors. The role of expressed human bradykinin B2 receptors and ACE in CHO cells. Circ Res 81:848-856.
31. Murakami N, Sakai N, Nei K, Matsuyama S, Saito N and Tanaka C (1994) Potassium and calcium channel involvement in induction of long-lasting synaptic enhancement by calyculin A, a protein phosphatase inhibitor, in rat hippocampal CA1 region. Neurosci Lett 176:181-184.
32. Pfeffer MA, Braunwald I, Moye LA and the SAVE Investigators (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327:669-677.
33. Pitcher JA, Freedman NJ and Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653-692.
34. Pizard A, Marchetti J, Allegrini J, Alhenc-Gelas F and Rajerison RM (1998) Negative cooperativity in the human bradykinin B2 receptor. J Biol Chem 273:1309-1315.
35. Roberts RA and Gullick WJ (1990) Bradykinin receptors undergo ligand-induced desensitization. Biochemistry 29:1975-1979.
36. Skidgel RA and Erdös EG (1998) Enzymatic breakdown of bradykinin, in Proinflammatory and Anti-inflammatory Peptides (Said SI ed) pp 459-476, Marcel Dekker, New York.
37. ++ dependent protein kinase. Biochem Biophys Res Commun 135:397-402.
38. Yang HYT, Erdös EG and Levin Y (1971) Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J Pharmacol Exp Ther 177:291-300.